Odyssey Therapeutics raises $279 million in IPO, begins Nasdaq trading
read at Endpoints ↗DealPositive
Odyssey Therapeutics, a biotech focused on autoimmune diseases, announced that its initial public offering generated $279 million.
The company sold about 15.5 million shares and priced the IPO at a level that gave it a market debut on the Nasdaq on Friday.
Proceeds will be used to advance its pipeline of autoimmune drug candidates and support ongoing clinical programs.
source
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “Odyssey raises more than $300M as biotech goes public”
read at Endpoints ↗82 words · retrieved May 8
comments(0)
5-min edit window · permanent after that